FMP
Unicycive Therapeutics, Inc.
UNCY
NASDAQ
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
0.55 USD
-0.0721 (-13.11%)
Historical Prices
From:
To:
About
ceo
Dr. Shalabh K. Gupta M.D., MPA
sector
Healthcare
industry
Biotechnology
website
https://www.unicycive.comexchange
NASDAQ
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
CIK
0001766140
ISIN
US90466Y1038
CUSIP
90466Y103
Address
4300 El Camino Real
Phone
650 351 4495
Country
US
Employee
22
IPO Date
Jul 12, 2021
Financial Statement
Earnings
UNCY Financial Summary
CIK
0001766140
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
90466Y103
ISIN
US90466Y1038
Country
US
Price
0.55
Beta
2.13
Volume Avg.
900.38k
Market Cap
66.35M
Shares
-
52-Week
0.202-1.16
DCF
0.04
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.98
P/B
-
Website
https://www.unicycive.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest UNCY News
GlobeNewsWire
Aug 26, 2024
Unicycive Therapeutics to Present Three Posters at the Ameri...
LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that three poster presentations will be delivered on the Company's product candidates at the American Society of Nephrology (ASN) Kidney Week 2024 taking place October 24-27, 2024 in San Diego, CA.
GlobeNewsWire
Jul 11, 2024
Unicycive Therapeutics to Participate in Fireside Chat at th...
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024 at 2:00 p.m. ET.
GlobeNewsWire
May 23, 2024
Unicycive Therapeutics to Participate in a Fireside Chat at ...
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the virtual Lytham Partners Spring 2024 Investor Conference on Thursday, May 30, 2024, at 9:30 a.m. ET.
GlobeNewsWire
Apr 10, 2024
Unicycive Therapeutics to Present at the Noble Capital Marke...
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company update at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on Thursday April 18, 2024 at 11:00 a.m. ET.
GlobeNewsWire
Feb 14, 2024
Unicycive Therapeutics to Present Two Posters on Oxylanthanu...
LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company's lead product candidate, oxylanthanum carbonate (OLC), will be presented at the National Kidney Foundation Spring Clinical Meeting taking place May 14-18, 2024, in Long Beach, California.
Zacks Investment Research
Jan 24, 2024
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Upda...
Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.
GlobeNewsWire
Nov 29, 2023
Unicycive Therapeutics to Participate in Two Investor Confer...
LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023.
InvestorPlace
Oct 6, 2023
The 7 Most Undervalued Penny Stocks to Buy in October 2023
Investing in undervalued penny stocks is always going to be about the same few things. Most investors are attempting to find cheap, short-term plays with reasonable catalysts in their favor.
